title: Predictive value of serum insulin-like growth factor-1 in hepatocellular carcinoma.
abstract: BACKGROUND
  Hepatocellular carcinoma (HCC) is the commonest primary malignant cancer of the liver in the world. Insulin-like growth factor-1 (IGF-1) levels reflect hepatic function and are inversely correlated with the severity of background chronic liver disease.
  
  
  OBJECTIVE
  This study evaluated whether basal serum IGF-1 levels can predict prognosis of HCC patients according to different risks of disease progression.
  
  
  METHODS
  A total of 89 patients with hepatocellular carcinoma (HCC) were recruited in 3 groups: Group I, 30 HCC patients receiving sorafinib; Group II, 30 HCC patients with best supportive care; and Group III include 29 patients undergoing transcatheter arterial chemoembolization (TACE). All patients were investigated for serum levels of AST, ALP, Bb, Cr, BUN, AFP and IGF-I.
  
  
  RESULTS
  Patients with disease control had significantly higher baseline IGF-1 levels 210 (185-232.5) ng/mL (p value<0.01) than did patients without disease control. Low basal IGF-1 levels were associated with advanced HCC, such as multiple tumors and advanced stage, and low IGF-1 levels predicted shorter TTP and overall survival in patients treated with TACE.
  
  
  CONCLUSIONS
  The levels of serum IGF-1, expressed as continuous values, may be helpful for accurately assessing hepatic function and the prognostic stratification of patients with HCC.
authors: Clinical Oncology, University of Tanta, Tanta, Egypt E-mail : nehalelmashad@yahoo.com.
authors: Nehal
authors: N
authors: Elmashad
authors: Wesam Salah
authors: WS
authors: Ibrahim
authors: Wael Wahid
authors: WW
authors: Mayah
authors: Mohamed
authors: M
authors: Farouk
authors: Lobna Abo
authors: LA
authors: Ali
authors: Atef
authors: A
authors: Taha
authors: Wael
authors: W
authors: Elmashad
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D008113:Liver Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D011379:Prognosis; D000077157:Sorafenib; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D010671:Phenylurea Compounds; D009536:Niacinamide; D007334:Insulin-Like Growth Factor I; D000077157:Sorafenib